Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by Ingiboyon Nov 04, 2022 10:33am
175 Views
Post# 35072930

Update

UpdateI think most of us here are wondering why we have not received an update.  So many unanswered questions.  It is now past a year since the Shiseido Arbitration began with no idea of where this process is at.  We have also no idea of what is happening with the Dermal injector.  The shareholders have a right to know.
 What is the reason for this ? I am beginning to think they are holding back an update until after the close of the current Private Placement on Nov. 18th.  Why would they do that ?  I think the reason being is that the news is not all that great.  The Arbitration process could go on for months.  The Dermal Injector is simply not ready for submission for FDA Approval.  This doesn't mean the Arbitration Judgement will go against Relpicel and the Dermal injector is a bust.  It means that we thought that by the end of 2022 an Arbitration Judgement would have been rendered and the Dermal Injector would begin being marketed.
This obviously is not going to be the case as we come to the end of 2022.  There is no question that there will be an update at some point but I would not expect one until after Nov. 18th.  

 
<< Previous
Bullboard Posts
Next >>